Theranostic applications of smart nanomedicines for tumor-targeted chemotherapy: a review

Cancer is the result of disturbed cell functions. Cancer is induced by the accumulation of many genetic and epigenetic changes within the cell, expressed in the accumulation of chromosomal or molecular aberrations, which then leads to genetic instability. Chemotherapy is a major option to treat canc...

Full description

Saved in:
Bibliographic Details
Published in:Environmental chemistry letters 2020-09, Vol.18 (5), p.1509-1527
Main Authors: Juthi, Ajkia Zaman, Aquib, Md, Farooq, Muhammad Asim, Ghayas, Sana, Khalid, Farah, Boafo, George Frimpong, Wande, Dickson Pius, Khan, Daulat Haleem, Bithi, Tasnim Zaman, Bavi, Rohit, Wang, Bo
Format: Article
Language:English
Subjects:
Accumulation
Analytical Chemistry
Antitumor agents
Cancer
Chemotherapy
Chromosomes
Drug delivery systems
Earth and Environmental Science
Ecotoxicology
Endocytosis
Environment
Environmental Chemistry
Genomic instability
Geochemistry
Localization
Neoplasms
Permeability
Pollution
Receptors
Review
Toxicity
Tumors
Uptake
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer is the result of disturbed cell functions. Cancer is induced by the accumulation of many genetic and epigenetic changes within the cell, expressed in the accumulation of chromosomal or molecular aberrations, which then leads to genetic instability. Chemotherapy is a major option to treat cancer, yet classical treatments induce toxic effects. Alternatively, cancer nanomedicines with tumor-targeted properties are very promising for improved safety and efficacy. Nanomedicines are sub-micrometer formulations designed to improve the biodistribution of anticancer drugs, resulting in modified toxicity, less off-target localization, enhanced efficacy and improved accumulation at the target site. For designing a targeted nanodrug system, the pathophysiological characteristics of tumors should be studied. This article explains how to make smart nanomedicines based on tumor-associated pathological features. Advantages include selective cell uptake, better drug release, increased therapeutic efficiency, receptor-mediated cell endocytosis, enhanced permeability and retention, and reduced systemic effects.
ISSN:1610-3653
1610-3661
DOI:10.1007/s10311-020-01031-8